Trianni in License Agreement with Nkarta for Trianni Mouse

March 27, 2020
Pharmaceutical Technology Editors

Pharmaceutical Technology's In the Lab eNewsletter

In the Lab eNewsletter, Pharmaceutical Technology's In the Lab eNewsletter-04-01-2020, Volume 15, Issue 4
Page Number: 12

The transgenic mouse R&D platform will support the discovery of fully-human monoclonal antibodies.

Trianni, a San Francisco, CA-based privately held biotech company specializing in antibody discovery technology, has entered into a license agreement with Nkarta, another San Francisco-based biotechnology company specializing in cancer therapeutics based on natural killer cells, for the use of the Trianni Mouse, a transgenic mouse R&D platform for the discovery of fully-human monoclonal antibodies. The agreement supports Nkarta’s antibody-based therapeutic discovery programs, the companies announced in a March 10, 2020 press release.

“[Trianni] is pleased to add [Nkarta] as a new licensee of the Trianni Mouse,” stated Matthias Wabl, PhD, Trianni’s president and CEO, in the press release. “We are confident that combining “[Trianni]’s powerful antibody discovery platform with [Nkarta]’s unique proprietary technology will facilitate [Nkarta]’s development of novel cell-based therapeutics.”

Source: Trianni